Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. TME Pharma N.V.
  6. News
  7. All News
    ALTME   NL0015000YE1

TME PHARMA N.V.

(ALTME)
  Report
Real-time Euronext Paris  -  11:21:10 2023-01-27 am EST
1.150 EUR   -3.97%
01/23Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Combination with Radiotherapy and Bevacizumab in Patients with Glioblastoma
CI
01/20Tme Pharma N : Half-yearly report on the liquidity contract with Invest Securities
PU
2022Tme Pharma N : announces convocation of an extraordinary general meeting of shareholders
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about TME PHARMA N.V.
01/23Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Comb..
CI
01/20Tme Pharma N : Half-yearly report on the liquidity contract with Invest Securities
PU
2022Tme Pharma N : announces convocation of an extraordinary general meeting of shareholders
PU
2022Biotech Group TMA Pharma's CFO to Leave by 2022-end
MT
2022Tme Pharma N : announces the resignation of its Chief Financial Officer Bryan Jennings
PU
2022TME Pharma N.V. Announces Executive Changes
CI
2022TME Pharma N.V. Announces the Resignation of Bryan Jennings as Chief Financial Officer
CI
2022Tme Pharma N : The presentation
PU
2022TME Pharma N.V. - POSITIVE UPDATED INTERIM RESULTS FROM NOX-A12 GLORIA PHASE 1/2 IN BRA..
AQ
2022TME Pharma Announces Positive Updated Interim Results from NOX-A12 GLORIA Phase 1/2 in ..
CI
2022Tme pharma announces publication of abstract disclosing positive interim results from b..
AQ
2022Tme Pharma N : to host key opinion leader webinar
PU
2022Tme Pharma N : announces publication of abstract disclosing positive interim results from ..
PU
2022TME Pharma Announces Publication of Abstract Disclosing Positive Interim Results from B..
CI
2022TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
2022Tme Pharma N : Inside Information / News release on accounts, results
PU
2022Tme Pharma N : 2022, Half-Year Financial Report as of 30 June 2022
PU
2022Tme pharma announces upcoming presentation at the society for neuro-oncology annual mee..
AQ
2022TME Pharma - SAFETY CONFIRMED OF NOX-A12 AND PEMBROLIZUMAB COMBINATION IN GLORIA PHASE ..
AQ
2022Data Safety Monitoring Board Validates Safety Data for TME Pharma's Brain Cancer Therap..
MT
2022TME Pharma N.V. Announces Data Safety Monitoring Board Validated Safety Data from the I..
CI
2022TME Pharma Treats First Brain Cancer Patient In Phase 1/2 Clinical Study
MT
2022TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-..
CI
2022Noxxon Pharma N : Inside Information / Other news releases
PU
2022French Drugmaker Noxxon Changes Name to TME Pharma
MT
2022Noxxon pharma announces changes to its supervisory board
AQ
2022Noxxon pharma - half-yearly report on the liquidity contract with invest securities
AQ
2022NOXXON Pharma N.V. Announces Resignation of Gregory Weaver from its Supervisory Board, ..
CI
2022Noxxon Pharma N : Bryan Jennings
PU
2022Noxxon Pharma N : 1 July 2022
PU
2022Noxxon Pharma N : AFM notification form MAR 19 – managers transactions
PU
2022Noxxon provides results of its 2022 annual general meeting of shareholders
AQ
2022Noxxon Pharma N : Download transcript
PU
2022NOXXON Pharma N.V. has Changed its Name to TME Pharma N.V
CI
2022Noxxon announces corporate action to start the parity period
AQ
2022NOXXON Announces Updated Development Strategy Following Strong Clinical Benefit Observe..
CI
2022Noxxon enters into collaboration with us national cancer institute to characterize effe..
AQ
2022NOXXON Pharma N.V. Enters into Amaterial Transfer Agreement with the U.S. National Canc..
CI
2022Noxxon Pharma N : KOL Event Presentation NOX-A12 Phase 1/2 GLORIA trial in glioblastoma
PU
2022Noxxon presents full top-line results from nox-a12 phase 1/2 gloria trial in glioblasto..
AQ
2022Noxxon to host key opinion leader webinar on gloria study top-line results of nox-a12 &..
AQ
2022NOXXON announces convocation of the 2022 annual general meeting of shareholders
AQ
2022NOXXON Announces Presentation of NOX-A12 Phase 1/2 Data in Glioblastoma at The 2022 ASC..
CI
2022Noxxon amends equity-linked facility with atlas
AQ
2022Noxxon Obtains Additional $1 Million in Remaining Tranches of Equity-linked Facility
MT
2022Noxxon announces results of the extraordinary general meeting of shareholders
AQ
2022Noxxon Pharma N.V. Announces Scientific Advisory Board Appointments
CI
2022TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2022Noxxon announces eur2.375 million financing under agreement with atlas
AQ
2022NOXXON Pharma N.V. Auditor Raises 'Going Concern' Doubt
CI
2022Top-line results from noxxon's nox-a12 phase 1/2 gloria trial in brain cancer to be pre..
AQ
2022Noxxon Pharma N : Top-line results from NOXXONs NOX-A12 Phase 1/2 GLORIA trial in brain ca..
PU
2022Top-Line Results from NOXXON’S NOX-A12 Phase 1/2 GLORIA Trial in Brain Cancer to B..
CI
2022NOXXON Announces Top-Line Data of Phase 1/2 GLORIA Study With NOX-A12 in Partially Rese..
CI
2022Noxxon announces eur2.375 million financing under agreement with atlas
AQ
2022Cancer-Focused Biotech Noxxon Secures Additional $2.7 Million Financing
MT
2022Noxxon - half-yearly report on the liquidity contract with invest securities
AQ
2022Noxxon provides progress update on the expansion arms of the phase 1/2 gloria trial wit..
AQ
2022NOXXON Provides Progress Update on the Expansion Arms of the Phase 1/2 GLORIA Trial Wit..
CI
2022Noxxon provides update on evaluation of nox-a12 in non- oncology indication by a leadin..
AQ
2022NOXXON Pharma N.V. Provides Update on Evaluation of NOX-A12 in Non-Oncology Indication ..
CI
2022NOXXON Pharma N.V. announced that it expects to receive €17 million in funding
CI
2021Noxxon Gets Additional $19 Million Funding From Atlas Special Opportunities
MT
2021Noxxon Pharma N : secures Euro 17 million expansion of equity-linked facility with Atlas t..
PU
2021NOXXON Pharma N.V. Announces Appointment of Bryan Jennings as Additional Statutory Dire..
CI
2021Noxxon Pharma N : announces results of the extraordinary general meeting of shareholders
PU
2021Noxxon Pharma N : to participate in banking and investor conferences in January and Februa..
PU
2021Global markets live: Intel, Tesla, Facebook, ABB, SGS...
MS
2021NOXXON Pharma N.V. Announces Enrolment of First Patient in the Expansion of the NOX-A12..
CI
2021NOXXON Pharma N.V. Presents New Phase 1/2 Data On NOX-A12 & Radiotherapy Combination in..
CI
2021Noxxon : New Phase 1/2 data on NOX-A12 & radiotherapy combination in brain cancer presente..
PU
2021Noxxon Pharma N : Presentation by Dr. Frank Giordano at the Society for Neuro-Oncology (SN..
PU
2021Noxxon to host key opinion leader webinar on nox-a12 and radiotherapy combination, a di..
AQ
2021Noxxon To Host Key Opinion Leader We : a differentiated and promising new approach to trea..
PU
2021Noxxon Pharma N : announces convocation of an Extraordinary General Meeting of shareholder..
PU
1  2  3  4  5Next
Upcoming event on TME PHARMA N.V.